Brain Metastases And Primary Brain Articles & Analysis
12 news found
Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases. ...
Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors including high-grade ...
xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM ...
ByxCures
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., ...
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO). Former CEO and Executive Chairman Jonathan Allis, D.Phil., assumes the role of Honorary Chairman of the Blue Earth Diagnostics Board of Directors. Dr. ...
Drs. Ondrej Choutka, MD, a neurosurgeon, and Lindsay Sales, MD, a radiation oncologist at Saint Alphonsus Regional Medical Center in Boise, have become the first doctors in the Pacific Northwest to utilize a new treatment for brain tumors. They implanted the FDA-cleared GammaTile therapy in a 44-year-old patient with a malignant brain tumor. The current standard of care for patients with ...
To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards ...
GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company's breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting. The presenting authors, Dr. David Brachman, co-founder and CTO at GT Medical Technologies and Dr. Mehee Choi, director ...
Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. ...
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
Data from the study will be used to benchmark clinical outcomes for GammaTile Therapy and allow for comparisons to existing standard-of-care treatments for patients with brain tumors. Over 700,000 Americans are living with a brain tumor today.1 Despite the efforts of the most skilled brain tumor specialists in the world, outcomes for patients ...